Immune response
Gene:
SPAG9 (official gene symbol)Other symbol:
SPAG9CT family:
CT89CT identifier:
CT89Aliases from NCBI:
FLJ13450 , FLJ14006 , FLJ26141 , FLJ34602 , HLC4 , HSS , JLP , KIAA0516 , MGC117291 , MGC14967 , MGC74461 , PHET , PIG6Humoral immune response
SPAG9 was identified in a SEREX screening in leukemia patients (Guinn et al., 2005 PMID: 16112646). SPAG9 is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies in these patients (Yasuoka et al., 2003 PMID: 14662895; Yasuoka et al., 2007 PMID: PMID: 17317613). Spontaneous humoral immune responses against SPAG9 have been reported in cancer patients:
| Tumor type | Tumor stage | Frequency | Antibody detection methodology | PMID |
|---|---|---|---|---|
| Serous ovarian adenocarcinoma | 11/19 (58%) | ELISA | 17332284 | |
| Clear-cell carcinoma | 2/2 (100%) | ELISA | 17332284 | |
| Mucinous ovarian carcinoma | 3/3 (100%) | ELISA | 17332284 | |
| Cervical carcinoma | 53/66 (80%) | ELISA | 19326449 | |
| Breast carcinoma | 80/100 (80%) | ELISA | 19190149 |
Cellular immune response
There are no published reports of spontaneous cellular immune responses against SPAG9 in cancer patients.
Induced immune response
There are no published reports that evaluated induced immune responses in patients vaccinated with SPAG9